Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00112

Target Information
NameArachidonate 5-lipoxygenase    
Type of targetSuccessful target    
DiseaseAdult respiratory distress syndrome
[ICD9: 518.5, 518.82   ICD10: J80]
Allergic diseases
[ICD9: 995.3   ICD10: T78.4]
Allergic rhinitis, unspecified
[ICD9: 472.0, 477, 995.3   ICD10: J00, J30, J31.0, T78.4]
Antigen-induced decrease in coronary flow and cardiac anaphylaxis
[ICD9: 995.0   ICD10: T78.2]
[ICD9: 493   ICD10: J45]
Bronchiolar carcinoma
[ICD9: 162   ICD10: C34]
Cerebral vasospasm
[ICD9: 443.9   ICD10: I73.9]
Cervical cancer
[ICD9: 180   ICD10: C53]
Chronic myeloid leukemia
[ICD9: 205.1   ICD10: C92.1]
Dermatological disorders[10]
Gastrointestinal cancers
[ICD9: 150-159   ICD10: C15-C26]
[ICD9: 580-582   ICD10: N00, N01, N03, N18]
Inflammatory bowel disease
[ICD9: 555, 556   ICD10: K50, K51]
Inflammatory lung disease[13]
Magnesium deficiency dermatitis
[ICD9: 692.9   ICD10: L20-L30]
[ICD9: 715   ICD10: M15-M19, M47]
Pancreatic cancer
[ICD9: 157   ICD10: C25]
Polyarthritis, unspecified[18]
Prion diseases[19]
[ICD9: 696   ICD10: L40]
Pulmonary fibrosis
[ICD9: 515, 516.3   ICD10: J84.1]
Sjogren-Larsson syndrome
[ICD9: 757.1   ICD10: Q87.1]
Ulcerative colitis
[ICD9: 556   ICD10: K51]
Urological cancers
[ICD9: 140-229   ICD10: C00-C96]
Drug(s)DiethylcarbamazineApprovedLymphatic filariasis[26]
MasoprocolApprovedProstate cancer[27]
LicofelonePhase IIIOsteoarthritis[32][33][34][16]
LinazolastPhase IIIInflammatory Disorders[10][3]
LinetastinePhase IIIInflammatory disease[10][3]
Leukotriene antagonistPhase IIIdiopathic pulmonary fibrosis[35]
ABT-761Discontinued in Phase IIIAsthma[7][36]
CJ-13610Discontinued in Phase IIAsthma[37]
LonapaleneDiscotinued in Phase IIIPsoriasis[10][38]
MK-591Discontinued in Phase IIUlcerative Colitis[39][40]
BioChemical ClassOxidoreductases acting on single donors    
EC NumberEC
PathwayArachidonic acid metabolism
Linoleic acid metabolism
Metabolic pathways
UniProt IDP09917
PDB Structure2ABV; 3O8Y; 3V92; 3V98; 3V99.    
Related US Patent6,344,563
Target ValidationClick to Find Target Validation Information.    
QSAR ModelClick to Find Target QSAR Model.    
Acanthus ilicifolius Linn[48]
Azelastine hydrochloride[14]
BW A360C[50]
BW A4C[51][52][50][52]
BW B218C[50]
BW B70C[50]
CGS 8515[54]
CV-6504 HCl[15]
Caffeic acid[56][57][19]
Chebulagic acid[58]
ICI 207968[52]
Leukotriene antagonist[35]
Nordihydroguaiaretic acid[62]
Quinacrine HCl[19]
Quinacrine azide[19]
Quinacrine dihydrochloride[19]
SB 202235[63]
SK&F 107649[12]
SK&F 86002[1]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42. To Reference
Ref 2Biochem Pharmacol. 2002 Dec 15;64(12):1767-75.Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. To Reference
Ref 3Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs. Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):815-9. To Reference
Ref 4Characterization and modulation of antigen-induced effects in isolated rat heart. J Cardiovasc Pharmacol. 1991 Oct;18(4):556-65. To Reference
Ref 5Leukotrienes in respiratory disease. Paediatr Respir Rev. 2001 Sep;2(3):238-44. To Reference
Ref 6A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array. Anticancer Res. 2000 Jul-Aug;20(4):2433-9. To Reference
Ref 7The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage. Neurosurgery. 2001 Nov;49(5):1205-12; discussion 1212-3. To Reference
Ref 8Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer. 2002 Apr 8;86(7):1188-96. To Reference
Ref 9Morphologic changes of apoptosis induced in human chronic myelogenous leukemia "blast" cells by SC41661A (Searle), a selective inhibitor of 5-lipoxygenase. Scanning Microsc. 1994;8(3):675-84; discussion 684-6. To Reference
Ref 10Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. To Reference
Ref 11Eicosanoid production by the human gastric cancer cell line AGS and its relation to cell growth. Cancer Res. 1992 Apr 1;52(7):1744-9. To Reference
Ref 12Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat. Kidney Int. 1994 May;45(5):1301-10. To Reference
Ref 13Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil. J Pharmacol Exp Ther. 1992 Aug;262(2):874-82. To Reference
Ref 14Magnesium deficiency dermatitis--changes in leukotriene levels and effects of azelastine hydrochloride on the dermatitis and leukotriene B4. Nippon Hifuka Gakkai Zasshi. 1990 Jun;100(7):757-60. To Reference
Ref 15Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991 May;39(5):920-9. To Reference
Ref 16Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J Rheumatol. 2002 Jul;29(7):1446-53. To Reference
Ref 17A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol. 2000 Sep;11(9):1165-70. To Reference
Ref 18Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide. Arzneimittelforschung. 1988 Mar;38(3):372-8. To Reference
Ref 19Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res. 2001 Sep 15;65(6):565-72. To Reference
Ref 20Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol. 1996;9(5):307-11. To Reference
Ref 21The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis. Am J Respir Crit Care Med. 2002 Jan 15;165(2):146-7. To Reference
Ref 225-Lipoxygenase inhibition: a new treatment strategy for Sj?gren-Larsson syndrome. Neuropediatrics. 2000 Feb;31(1):1-3. To Reference
Ref 23Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology. 1997 Mar;112(3):725-32. To Reference
Ref 24Lipoxygenase inhibitors prevent urological cancer cell growth. Int J Mol Med. 2004 May;13(5):665-8. To Reference
Ref 25Effect of 5-lipoxygenase inhibitor on experimental delayed cerebral vasospasm. Stroke. 1987 Mar-Apr;18(2):512-8. To Reference
Ref 26Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7. To Reference
Ref 27Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL. Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E593-600. To Reference
Ref 285-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Mar 23. [Epub ahead of print] To Reference
Ref 295-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009 Mar;19(3):244-7. To Reference
Ref 30Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells. J Neurosci Res. 2009 Mar;87(4):991-1001. To Reference
Ref 31Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008 Oct 15;14(20):6525-30. To Reference
Ref 32Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):99-108. Epub 2008 Feb 15. To Reference
Ref 33Activity and potential role of licofelone in the management of osteoarthritis. Clin Interv Aging. 2007;2(1):73-9. To Reference
Ref 34Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis. 2008 Feb;29(2):371-80. Epub 2007 Nov 21. To Reference
Ref 35Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46. To Reference
Ref 36N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett. 1999 Apr 5;9(7):979-84. To Reference
Ref 37Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. To Reference
Ref 38Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol. 1990 Jul;95(1):50-4. To Reference
Ref 39Antileukotriene therapy for asthma. Am J Health Syst Pharm. 1996 Dec 1;53(23):2821-30; quiz 2877-8. To Reference
Ref 40Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol. 1994 Jun 2;258(1-2):95-102. To Reference
Ref 41J Med Chem. 1998 May 21;41(11):1970-9.(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. To Reference
Ref 42The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. To Reference
Ref 43Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann N Y Acad Sci. 1994 Nov 15;744:262-73. To Reference
Ref 44Platelets stimulate airway smooth muscle cell proliferation through mechanisms involving 5-lipoxygenase and reactive oxygen species. Platelets. 2008 Nov;19(7):528-36. To Reference
Ref 45Leukotriene B4/leukotriene B4 receptor pathway is involved in hepatic microcirculatory dysfunction elicited by endotoxin. Shock. 2008 Jul;30(1):87-91. To Reference
Ref 46J Nat Prod. 1999 Sep;62(9):1241-5.Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. To Reference
Ref 47J Med Chem. 1997 Nov 7;40(23):3773-80.Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. To Reference
Ref 48Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12. Epub 2008 Jul 25. To Reference
Ref 49J Med Chem. 1991 Mar;34(3):1028-36.Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. To Reference
Ref 50Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99. To Reference
Ref 51Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas. Oncogene. 2009 Jul 23;28(29):2690-6. Epub 2009 Jun 8. To Reference
Ref 52Tumour necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions. 1991 Mar;32(3-4):289-94. To Reference
Ref 53J Med Chem. 1990 Apr;33(4):1163-70.Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes. To Reference
Ref 54Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models. Biochim Biophys Acta. 1988 Apr 15;959(3):332-42. To Reference
Ref 55J. Nat. Prod. 57(9):1290-1293 (1994) To Reference
Ref 56Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6. Epub 2008 Aug 22. To Reference
Ref 57Protection of mouse brain from aluminum-induced damage by caffeic acid. CNS Neurosci Ther. 2008 Spring;14(1):10-6. To Reference
Ref 58Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J Ethnopharmacol. 2009 Jul 30;124(3):506-12. Epub 2009 May 28. To Reference
Ref 59Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference
Ref 60J Med Chem. 1987 Nov;30(11):2121-6.In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. To Reference
Ref 615-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem. 2008 Feb;104(4):1091-100. Epub 2007 Nov 17. To Reference
Ref 62Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. Drug Metab Dispos. 2009 Aug;37(8):1733-7. Epub 2009 Apr 30. To Reference
Ref 63Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma. J Pharmacol Exp Ther. 1995 Jun;273(3):1147-55. To Reference
Ref 64Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. To Reference
Ref 65J Med Chem. 1998 Mar 26;41(7):1124-37.New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ring. To Reference
Ref 66Bioorg. Med. Chem. Lett. 4(20):2383-2388 (1994) To Reference
Ref 67Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48. To Reference
Ref 68Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur J Pharmacol. 2007 Dec 22;577(1-3):109-14. Epub 2007 Aug 14. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543